⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 22, 2025Open Access

Table S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

John D. Powderly Martina Imbimbo Antoîne Italiano Patricia Martín-Romano Meredith McKean Teresa Macarulla Eduardo Castañón Álvarez Benedito A. Carneiro Raymond Mager Vicky Barnhart Steven Eck Elina Murtomaki Arsène‐Bienvenu Loembé Yun He Zachary A. Cooper Eric Tu Chunling Fan Agnes Boyer Chamard Carine Paturel Paula G. Fraenkel Antoine Hollebecque

View Full Paper

Ask AI

Bookmark

Share

Key Points

Over 5% of patients experienced treatment-related adverse events during anti-CD39 mAb therapy, indicating potential safety issues.
The study focuses on anti-CD39 mAb, both as a standalone treatment and in combination with durvalumab for advanced solid tumors.
Observational analysis collects data on TRAEs to evaluate the safety profile of anti-CD39 compared to standard care.
These findings point to a need for careful monitoring of patients receiving this combination therapy.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Analysis reveals TRAEs in over 5% of patients receiving anti-CD39 mAb, suggesting safety concerns with treatments.

Abstract

TRAEs of any grade occurring in >5% of all patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Powderly et al. (2025) studied this question.

synapsesocial.com/papers/68d4725631b076d99fa6b16e https://doi.org/10.1158/2767-9764.30177700

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
2Table S3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
3Table 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
4Table S5 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025
5Table S4 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors2025